Company Category: Microscopes/Imaging/Image Analysis/Flow Cytometers

Charles River is a global preclinical oncology CRO delivering end to end oncology and immuno oncology drug discovery, from target identification and validation through IND enabling and clinical. We partner with academic, biotechnology, and pharmaceutical companies to advance innovative cancer therapies. In 2025, Charles River supported 87% of FDA-approved oncology therapies, including first-in-class and best-in-class drugs. Our capabilities span small molecules, biologics, antibodies, antibody drug conjugates (ADCs), immunotherapies, checkpoint inhibitors, cell therapies, and gene therapies. Our research model (RMS) portfolio includes immunodeficient mice and rats, PBMC and CD34+ humanized mouse models, end-to-end support from colony management for Genetically Engineered Model (GEM), including transgenic model generation and breeding, to vivarium rental or customizable onsite services (staffing, consulting, training), and CRADL® support in global biohubs. Our oncology platforms include 1,700+ xenograft models (PDX, CDX, syngeneic, humanized), covering 45+ cancer indications across solid tumors, hematologic, and pediatric cancers. Integrated in vitro, ex vivo, NAMs and 3D tumor models—including organoids, tumoroids, and tissue microarrays (TMAs)- support efficacy, PK/PD, biomarker, and translational decision making. Multi omics, AI enabled analytics, and strategic CMC/CDMO capabilities help teams plan manufacturing earlier, strengthen regulatory readiness, improve study design, reduce risk, and accelerate candidate to patients. Learn more at criver.com/cancer-research-annual-meeting-2026 | Charles River has supported researchers in advancing ocular therapies for more than two decades, with a comprehensive suite of capabilities designed to meet your program needs. We help you progress small molecules, biologics, gene and cell therapies, and implantable devices from concept to clinic with confidence. Our team provides rigorous efficacy, distribution, and safety assessments supported by state-of-the-art imaging, functional evaluations, and New Approach Methodologies (NAMs) to help you improve predictability and generate high-quality data for global regulatory submissions. We also assess the ocular effects of systemic compounds for non-ocular indications, helping you refine study design, manage timelines and resources, and reduce animal use. We are committed to partnering with you at every stage to help bring meaningful treatments to patients worldwide because every moment matters. | Charles River provides essential products and services to support pharmaceutical and biotechnology companies, government agencies, and leading academic institutions worldwide in accelerating research and drug development. As a leader in scientific innovation, we are deeply committed to pioneering alternative methods that drive discovery while reducing reliance on traditional models. By embracing cutting-edge technologies and forward-thinking approaches, we enhance preclinical and clinical research. Our dedicated employees focus on delivering precisely what our clients need to improve, innovate, and expedite the discovery, early-stage development, and safe manufacture of new therapies for patients—because every moment matters. Learn more at www.criver.com. | Charles River is committed to helping companies like yours get your product to market safely and efficiently. Whether you’re still in development or already manufacturing, our Safety Assessment and Microbial Solutions services provide state-of-the-art technology and expert regulatory advice that will help you anticipate challenges, avoid roadblocks, and make better decisions.